Earnings release
Page 1
NUTEX HEALTH REPORTS SEPTEMBER 30, 2025 THIRD QUARTER AND YEAR-TO-DATE FINANCIAL RESULTS • Total revenue of $723.6 million for the first nine months of 2025 versus $222.3 million for the first nine months of 2024, an increase of 225.5% • Net income attributable to Nutex Health Inc. of $59.0 million for the first nine months of 2025 versus net loss of $9.5 million for the first nine months of 2024, an increase of $68.5 million • Diluted income per share of $8.87 for the first nine months of 2025 versus a loss per share of $1.91 for the first nine months of 2024 • EBITDA of $142.9 million for the first nine months of 2025 versus $19.9 million for the first nine months of 2024, an increase of 616.4% • Adjusted EBITDA of $243.0 million for the first nine months of 2025 versus $16.1 million for the first half nine months of 2024, an increase of 1408.6% • Net cash from operating activities of $177.7 million for the first nine months of 2025 HOUSTON, TX − (PRNewswire) – NOVEMBER 19, 2025 – Nutex Health Inc. (“Nutex Health” or the “Company”) (NASDAQ: NUTX), today announced financial results for the three and nine months ended September 30, 2025. Nutex Health is a physician-led, integrated healthcare delivery system comprised of 24 state-of-the-art micro hospitals and hospital outpatient departments (HOPDs) in 11 states and primary care-centric, risk-bearing physician networks. Financial highlights for the three months ended September 30, 2025: • Total revenue increased $189.0 million to $267.8 million for the three months ended September 30, 2025 as compared to total revenue of $78.8 million for the same period in 2024, an increase of 239.9%. The hospital division drove most of this growth, generating $260.2 million, up 262.8% from $71.7 million for the third quarter of 2024. Revenue from mature hospitals, which are hospitals opened prior to December 31, 2021, increased by 208.9% in 2025 compared to 2024. • Of the $260.2 million in hospital revenue, $182.1 million (or approximately 70.0%) related to a combination of both higher acuity claims as well as success through the Independent Dispute Resolution (IDR) process. • With regard to arbitration-related revenue: due to the continual underpayment from payors, we have continued to submit between 60-70% of our visits through the IDR process, we have won a legal determination on over 85% of the claims submitted, and we currently have an average collection rate of over 80% of the legal determination wins. • Arbitration costs approximate 24-26% of the arbitration related revenue. • Total stock-based compensation expense for the three months ended September 30, 2025 was $13.2 million compared to $2.0 million for the same period in 2024. Approximately 99.5% of total stock-based compensation expense of $13.2 million is due to the one-time obligations for under-construction and ramping hospitals. • Operating income for the three months ended September 30, 2025 was $130.4 million compared to $9.7 million for the same period in 2024, representing a $120.7 million improvement year over year. • Net income attributable to Nutex Health for the three months ended September 30, 2025 of $55.4 million as compared to net loss attributable to Nutex Health of $8.8 million for the same period in 2024. The $55.4 million in net income includes non-cash stock-based compensation expense of $13.2 million, while the $8.8 million net loss includes non-cash stock-based compensation expense of $2.0 million. • EBITDA attributable to Nutex Health of $91.8 million, as compared to EBITDA attributable to Nutex Health of $4.3 million for the three months ended September 30, 2024, an increase of 2014.0%. • Adjusted EBITDA attributable to Nutex Health of $98.5 million, as compared to Adjusted EBITDA attributable to Nutex Health of $9.7 million for the three months ended September 30, 2024. • Total visits at the Hospital Division were 46,232 for the three months ended September 30, 2025, as compared to 41,668 for the same period in 2024, an increase of 4,564 or 11.0%. Visits at mature hospitals decreased by 0.6% in the three months ended September 30, 2025 as compared to the same period in 2024. • Net cash from operating activities of $99.5 million for the three months ended September 30, 2025. • As of September 30, 2025, the Company had total assets of $964.5 million, including cash and cash equivalents of $166.0 million, and long-term debt, net of $25.6 million. 1
Page 2
Financial highlights for the nine months ended September 30, 2025: • Total revenue increased $501.2 million to $723.6 million for the nine months ended September 30, 2025 as compared to total revenue of $222.3 million for the same period in 2024, an increase of 225.5%. The hospital division drove most of this growth, generating $700.5 million, up 251.4% from $199.4 million for the first nine months of 2024. Revenue from mature hospitals, which are hospitals opened prior to December 31, 2021, increased by 200.0% in 2025 compared to 2024. • Of the $700.5 million in hospital revenue, $462.9 million (or approximately 66.1%) related to a combination of both higher acuity claims as well as success through the IDR process. • With regard to arbitration-related revenue: due to the continual underpayment from payors, we have continued to submit between 60-70% of our visits through the IDR process, we have won a legal determination on over 85% of the claims submitted, and we currently have an average collection rate of over 80% of the legal determination wins. • Arbitration costs approximate 24-26% of the arbitration related revenue. • Total stock-based compensation expense for the nine months ended September 30, 2025 was $119.6 million compared to $2.0 million for the same period in 2024. Approximately 99.5% of total stock-based compensation expense of $119.6 million is due to the one-time obligations for under-construction and ramping hospitals. • Operating income for the nine months ended September 30, 2025 was $244.7 million compared to $16.4 million for the same period in 2024, representing a $228.3 million improvement year over year. • Net income attributable to Nutex Health for the nine months ended September 30, 2025 of $59.0 million as compared to net loss attributable to Nutex Health of $9.5 million for the same period in 2024. The $59.0 million in net income includes non-cash stock-based compensation expense of $119.6 million, while the $9.5 million net loss includes non-cash stock-based compensation expense of $2.0 million. • EBITDA attributable to Nutex Health of $142.9 million, as compared to EBITDA attributable to Nutex Health of $19.9 million for the nine months ended September 30, 2024, an increase of 616.4%. • Adjusted EBITDA attributable to Nutex Health of $243.0 million, as compared to Adjusted EBITDA attributable to Nutex Health of $16.1 million for the nine months ended September 30, 2024. • Total visits at the Hospital Division were 140,074 for the nine months ended September 30, 2025, as compared to 122,944 for the same period in 2024, an increase of 17,130 or 13.9%. Visits at mature hospitals increased by 1.8% in the nine months ended September 30, 2025 as compared to the same period in 2024. • Net cash from operating activities of $177.7 million for the nine months ended September 30, 2025. Note: EBITDA and Adjusted EBITDA are non-GAAP financial metrics. A reconciliation of non-GAAP to GAAP measures is included below in this earnings release. “We are continuing to add to a record year with 225% revenue growth, Adjusted EBITDA attributable to Nutex Health of $243.0 million, a 629% increase in gross profit and a record high cash balance of $166.0 million. Our financial performance highlights the strength of the business model with our strong balance sheet positioning us well for our planned growth strategy,” stated Jon Bates, Chief Financial Officer of Nutex Health. “We are very pleased to deliver another successful and profitable quarter. With the audit revisions and related activities behind us, our team is fully focused on driving future growth both within existing operations and through new facilities. Our pipeline remains strong, reflecting continued demand for small hospitals across the country,” stated Tom Vo, M.D., MBA, Chairman and Chief Executive Officer of Nutex Health. For more details on the Company’s financial results for the three and nine months ended September 30, 2025, please refer to our Quarterly Report on Form 10-Q filed with the U.S. Securities & Exchange Commission and accessible at www.sec.gov. Nutex Health Inc. Regains Nasdaq Compliance On November 19, 2025 Nutex received a letter from Nasdaq Listing Qualifications confirming that the Company has regained compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of periodic reports with the Securities and Exchange Commission. The letter states that following the Company’s filing of its Form 10-Q for the period ended June 30, 2025 on November 18, 2025, Nasdaq has determined that Nutex Health Inc. now complies with the rule and that the matter is closed. No further action is required by the Company in connection with this matter. Conference Call on Restated 2024 and First Three Quarters of 2025 Results 2
Page 3
The Company will host a conference call on Tuesday, December 2, 2025 at 10:30 a.m. ET to discuss its restated fiscal year 2024 results and its results for the first three quarters of 2025. Participant Listening: 1-877-407-9208 or 1-201-493-6784 Participant Link: https://callme.viavid.com/viavid/?callme=true&passcode=13746493&h=true&info=company&r=true&B=6 To access the call, please dial in approximately five minutes before start time. Those who are unable to attend the live conference call may access the recording on the Company's website. 3
Page 4
NUTEX HEALTH INC. CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) 4
Page 5
(In thousands, except share and per share amounts) September 30, 2025 December 31, 2024 Assets Current assets: Cash and cash equivalents $ 166,048 $ 40,640 Restricted short-term investments — 2,941 Accounts receivable 387,409 232,449 Accounts receivable - related parties 7,353 3,602 Inventories 3,158 2,850 Income tax receivable 12,097 — Prepaid expenses and other current assets 16,586 9,997 Total current assets 592,651 292,479 Property and equipment, net 82,821 77,933 Operating lease right-of-use assets 27,354 27,872 Financing lease right-of-use assets 225,719 218,889 Intangible assets, net 21,555 15,530 Goodwill, net 13,919 13,919 Deferred tax assets — 7,987 Other assets 499 711 Total assets $ 964,518 $ 655,320 Liabilities and Equity Current liabilities: Accounts payable $ 45,475 $ 9,614 Accounts payable - related parties 4,082 806 Lines of credit 5,304 3,554 Current portion of long-term debt 18,004 14,395 Operating lease liabilities, current portion 2,111 2,080 Financing lease liabilities, current portion 7,108 7,705 Accrued arbitration expenses 64,313 47,742 Accrued income tax expense — 26,533 Accrued stock-based compensation 11,194 16,356 Accrued expenses and other current liabilities 27,865 25,440 Total current liabilities 185,456 154,225 Long-term debt, net 25,574 22,466 Operating lease liabilities, net 30,423 30,617 Financing lease liabilities, net 270,077 259,479 Deferred tax liabilities 14,955 — Total liabilities 526,485 466,787 Commitments and contingencies (Note 10) Equity: Common stock, $0.001 par value; 950,000,000 shares authorized; 6,905,262 and 5,511,452 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively 7 6 Additional paid-in capital 615,180 489,409 Accumulated deficit (298,021) (356,976) Nutex Health Inc. equity 317,166 132,439 Noncontrolling interests 120,867 56,094 Total equity 438,033 188,533 Total liabilities and equity $ 964,518 $ 655,320 5
Page 6
NUTEX HEALTH INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) Three Months Ended September 30, Nine Months Ended September 30, (In thousands, except share and per share amounts) 2025 2024 2025 2024 Revenue: Hospital division $ 260,239 $ 71,733 $ 700,488 $ 199,367 Population health management division 7,565 7,062 23,090 22,964 Total revenue 267,804 78,795 723,578 222,331 Operating costs and expenses: Payroll 38,817 29,848 109,961 85,249 Contract services 53,837 11,657 153,601 32,482 Medical supplies 3,307 3,983 11,920 12,894 Depreciation and amortization 5,003 4,972 15,343 13,691 Other 11,959 6,418 34,610 23,380 Total operating costs and expenses 112,923 56,878 325,435 167,696 Gross profit 154,881 21,917 398,143 54,635 Corporate and other costs: Stock-based compensation 13,217 1,964 119,606 1,952 Impairment of assets — 425 — 3,899 Impairment of goodwill — — — 3,197 General and administrative expenses 11,297 9,865 33,830 29,175 Total corporate and other costs 24,514 12,254 153,436 38,223 Operating income 130,367 9,663 244,707 16,412 Interest expense, net 5,452 5,381 17,250 14,880 Loss on warrant liability — 6,734 — 1,073 Other (income) expense 976 128 8,570 (711) Income (loss) before taxes 123,939 (2,580) 218,887 1,170 Income tax expense 27,140 4,585 55,138 5,868 Net income (loss) 96,799 (7,165) 163,749 (4,698) Less: net income attributable to noncontrolling interests 41,364 1,623 104,794 4,819 Net income (loss) attributable to Nutex Health Inc. $ 55,435 $ (8,788) $ 58,955 $ (9,517) Earnings (loss) per common share Basic $ 8.27 $ (1.72) $ 9.63 $ (1.91) Diluted $ 7.76 $ (1.72) $ 8.87 $ (1.91) 6
Page 7
NUTEX HEALTH INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) 7
Page 8
Nine Months Ended September 30, (In thousands) 2025 2024 Cash flows from operating activities: Net income $ 163,749 $ (4,698) Adjustment to reconcile net income to net cash from operating activities: Depreciation and amortization 15,343 13,691 Loss on warrant liability — 1,073 Impairment of assets — 3,899 Impairment of goodwill — 3,197 Derecognition of goodwill — 453 Stock-based compensation expense 119,606 1,952 Changes to deferred taxes 22,942 (1,743) Debt accretion expense 756 805 Changes in operating assets and liabilities: (Increase)/Decrease in Accounts receivable (154,960) (4,253) (Increase)/Decrease in Accounts receivable - related party (3,751) 550 (Increase)/Decrease in Inventories (308) 1,131 (Increase)/Decrease in Income tax receivable (12,097) — (Increase)/Decrease in Prepaid expenses and other current assets (6,376) (1,361) (Increase)/Decrease in Operating right-of-use assets 518 411 Increase/(Decrease) in Accounts payable 36,637 (7,975) Increase/(Decrease) in Accounts payable - related party 3,276 (39) Increase/(Decrease) in Operating lease liabilities (164) (692) Increase/(Decrease) in Accrued arbitration expenses 16,571 — Increase/(Decrease) in Accrued income tax expense (26,533) — Increase/(Decrease) in Accrued expenses and other current liabilities 2,527 16,698 Net cash provided by operating activities 177,736 23,099 Cash flows from investing activities: Acquisitions of property and equipment (1,117) (1,909) Proceeds from restricted short-term investment 2,941 — Cash related to sale of business — (361) Cash related to asset acquisition (1,994) — Net cash used in investing activities (170) (2,270) Cash flows from financing activities: Proceeds from lines of credit 5,043 1,132 Proceeds from notes payable 273 7,015 Repayments of lines of credit (3,293) (1,119) Repayments of notes payable (8,319) (8,332) Repayments of finance leases (4,004) (1,924) Proceeds from common stock issuance, net issuance costs — 9,202 Proceeds from exercise of warrants — 801 Members' contributions 316 961 Members' distributions (42,174) (3,659) Net cash provided by (used in) financing activities (52,158) 4,077 Net increase in cash and cash equivalents 125,408 24,906 Cash and cash equivalents - beginning of the period 40,640 22,002 Cash and cash equivalents - end of the period $ 166,048 $ 46,908 8
Page 9
Non-GAAP Financial Measures (Unaudited) EBITDA and Adjusted EBITDA. EBITDA and Adjusted EBITDA are used as a supplemental non-GAAP financial measure by management and external users of our financial statements, such as industry analysts, investors, lenders and rating agencies. We believe EBITDA and Adjusted EBITDA are useful because it allows us to more effectively evaluate our operating performance. We define EBITDA as net income (loss) attributable to Nutex Health Inc. plus interest expense, income taxes, depreciation and amortization. We define Adjusted EBITDA as net income (loss) attributable to Nutex Health Inc. plus net interest expense, income taxes, depreciation and amortization, further adjusted for stock-based compensation, certain defined items of expense and any acquisition-related costs and impairments. Interest expense includes interest on lease liabilities, which is a component of total finance lease cost. A reconciliation of net loss to Adjusted EBITDA is included below. Beginning in the first quarter of 2025, we have updated our presentation of Adjusted EBITDA to separately disclose finance lease payments related to leases under ASC 842. We believe this change provides greater transparency into our operating performance. Adjusted EBITDA is not intended to serve as an alternative to U.S. GAAP measures of performance and may not be comparable to similarly-titled measures presented by other companies. Adjusted EBITDA follows (in thousands): Three Months Ended September 30, 2025 2024 Reconciliation of net income (loss) attributable to Nutex Health Inc. to Adjusted EBITDA: (Updated) (Prior) (Updated) (Prior) Net income (loss) attributable to Nutex Health Inc. $ 55,435 $ 55,435 $ (8,788) $ (8,788) Depreciation and amortization 5,003 5,003 4,972 4,972 Interest expense, net 5,452 5,452 5,381 5,381 Income tax expense 27,140 27,140 4,585 4,585 Allocation to noncontrolling interests (1,243) (1,243) (1,808) (1,808) EBITDA 91,787 91,787 4,342 4,342 Loss on warrant liability — — 6,734 6,734 Impairment of assets — — 424 424 Finance lease payments (6,474) — (3,794) — Stock-based compensation 13,217 13,217 1,964 1,964 Adjusted EBITDA $ 98,530 $ 105,004 $ 9,670 $ 13,464 (1) 9
Page 10
Nine Months Ended September 30, 2025 2024 Reconciliation of net income (loss) attributable to Nutex Health Inc. to Adjusted EBITDA: (Updated) (Prior) (Updated) (Prior) Net income (loss) attributable to Nutex Health Inc. $ 58,955 $ 58,955 $ (9,517) $ (9,517) Depreciation and amortization 15,343 15,343 13,691 13,691 Interest expense, net 17,250 17,250 14,880 14,880 Income tax expense 55,138 55,138 5,868 5,868 Allocation to noncontrolling interests (3,815) (3,815) (4,980) (4,980) EBITDA 142,871 142,871 19,942 19,942 Loss on warrant liability — — 1,073 1,073 Impairment of assets — — 3,898 3,898 Impairment of goodwill — — 3,197 3,197 Finance lease payments (19,512) — (13,957) — Stock-based compensation 119,606 119,606 1,952 1,952 Adjusted EBITDA $ 242,965 $ 262,477 $ 16,105 $ 30,062 Finance lease payments consist of cash payments for financing leases under ASC 842, which should be deducted from EBITDA. We believe this change is useful to investors to evaluate the ongoing operating performance of our business. (1) (1) 10
Page 11
About Nutex Health Inc. Headquartered in Houston, Texas and founded in 2011, Nutex Health Inc. (NASDAQ: NUTX) is a healthcare management and operations company with two divisions: a Hospital Division and a Population Health Management Division. The Hospital Division owns, develops and operates innovative health care models, including micro-hospitals, specialty hospitals, and hospital outpatient departments (HOPDs). This division owns and operates 24 facilities in 11 states. The Population Health Management division owns and operates provider networks such as Independent Physician Associations (IPAs). Through our Management Services Organization (MSO), we provide management, administrative and other support services to our affiliated hospitals and physician groups. 11
Page 12
Forward-Looking Statements Certain statements and information included in this press release constitute “forward-looking statements” within the meaning of the Private Securities Litigation Act of 1995. When used in this press release, the words or phrases “will”, “will likely result” “expected to,” “will continue,” “anticipated,” “estimate,” “projected,” “intend,” “goal,” or similar expressions are intended to identify “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include, but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, including the interim final and final rules implemented under the No Surprises Act, economic conditions, dependence on management, dilution to stockholders, lack of capital, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company’s ability to compete, conflicts of interest in related party transactions, regulatory matters, protection of technology, lack of industry standards, the effects of competition and the ability of the Company to obtain future financing. An extensive list of factors that can affect future results are discussed in the Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent Quarterly Report on Form 10-Q for the three and nine months ended September 30, 2025 under the heading “Risk Factors” in Part II, Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release. FOR ADDITIONAL INFORMATION: Nutex Health, Inc. Jennifer Rodriguez – Investor Relations investors@nutexhealth.com – Media Contact jrodriguez@nutexhealth.com 12